A Study of Dexamethasone - Cyclophosphamide Pulse Therapy in Pemphigus Patients by Seethalakshmi, V
A STUDY OF DEXAMETHASONE - CYCLOPHOSPHAMIDE 
PULSE THERAPY IN PEMPHIGUS PATIENTS
Dissertation submitted 
in partial fulfillment for the Degree of 
DOCTOR OF MEDICINE
BRANCH – XII A
M.D., (DERMATO VENEREOLOGY)
MARCH 2008
                   DEPARTMENT OF DERMATO VENEREOLOGY
       MADURAI MEDICAL COLLEGE
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY
CHENNAI – TAMILNADU
CERTIFICATE
This  is  to  certify  that  this  dissertation  entitled  “A  STUDY  OF 
DEXAMETHASONE-CYCLOPHOSPHAMIDE  PULSE  THERAPY  IN 
PEMPHIGUS PATIENTS” submitted by Dr.V.Seethalakshmi to The Tamil Nadu 
DR. M.G.R. Medical university, Chennai is in partial fulfillment of the requirement 
for the award of M.D. Degree Branch XII A, M.D., (Dermato Venereology) and is a 
bonafide research work carried out by her under direct supervision and guidance.
Dr.S.Krishnan, M.D., D.D   Dr.H.Syed Maroof Saheb,M.D.,D.D
Additional Professor,    Professor and Head,
Department of Dermatology,    Department of Dermatology,
Govt. Rajaji Hospital,    Govt. Rajaji Hospital,
Madurai Medical College,    Madurai Medical College,
Madurai.    Madurai.
ACKNOWLEDGEMENT
Gratitude  cannot  be  expressed  through  words.  True,  but  unexpressed 
gratefulness weighs heavily on one’s heart. I may be permitted here to record valuable 
guidance,  help,  co-operation and encouragement  from my teachers,  colleagues  and 
various  other  persons  directly  or  indirectly  involved  in  the  preparation  of  this 
dissertation.
First of all I would like to acknowledge my thanks and sincere gratitude to our 
beloved  Prof.Dr.H.Syed Maroof Saheb, Professor and Head of the Department of 
Dermatology,  Prof.Dr.N.Nagarajan,  Professor  and  Head  of  the  Department  of 
Venereology, GRH & MMC, Madurai for  their  valuable advice and encouragement.
I  profoundly  thank Dr.S.Krishnan, Addl.  Professor,  Department  of 
Dermatology, MMC & GRH, for his valuable guidance.
I  express  my  deep  sense  of  gratitude  and  thanks  to  my  teachers 
Dr.G.Geetharani,  Reader in Department  of Dermatology,  Dr.A.K.P.Vijayakumar 
and Dr. M. Subramania Adityan Assistant Professors, for their valuable guidance, 
timely advice, constant encouragement and easy approachability in the preparation of 
this  dissertation.  Their  profound  knowledge  in  Dermatology  gave  me  immense 
confidence throughout the study.
I  would  also  like  to  acknowledge  my  thanks  to  my  teachers 
Dr.A.S.Krishnaram,  Dr.K.Senthilkumar,  Dr.S.Ragunath,  Dr.Amalraja, 
Dr.R.Shanmuganathan, Dr.M.Vijayalakshmi, Assistant Professors, Department of 
DermatoVenereology,  MMC  &  GRH,  Madurai,  for  their  constant  support  and 
encouragement.
I owe thanks to the Dean, Principal and Medical Superintendent for allowing 
me to conduct this study.
I owe thanks to my fellow postgraduate colleagues for their constant help and 
constructive criticism.
I owe a lot to my family  which has always stood by me in my career.
I owe a lot to all my patients without whom this study would not have taken 
off,  and  the  authors,  who have  worked on  this  subject,  from whose  wisdom and 
experience. I have been benefited immensely.
CONTENTS
S.NO Particulars Page No.
1 Introduction                1
2 Review of literature                3
3 Aim of the Study       27
4 Materials and Methods      28
5 Observations and Results     30
6 Discussion     43
7 Conclusion     49
8 Bibliography     50
9 Annexures
                                    −Photographs
                                    −Proforma
                                    −Master chart
                                    − Key to master chart
INTRODUCTION
INTRODUCTION
The term “Pulse Therapy” has been used for a system of administering drugs 
in which a very high dose of the drug is given over a very short period for getting a 
quick result, and then the drug is withdrawn completely till it is needed or used again1.
Pulse  therapy  (the  big  shot)2 defined  as  administration  of  large  (supra 
pharmacological) dose of drugs in an intermittent manner, to enhance the therapeutic 
effects and to reduce the iatrogenic side effects of drugs.
It  is a relatively recent concept;  this  method has been observed to produce 
superior therapeutic results which cannot be produced by the conventional methods of 
giving  daily  dosages  while  the  side  effects  of  the  drugs  are  reduced  very 
significantly3.
The list of dermatological  indications for pulse therapy is increasing day by 
day and now it includes pemphigus and other autoimmune bullous diseases, collagen 
vascular diseases like systemic lupus erythematosus, progressive systemic sclerosis, 
Dermatomyositis,  allergic  vasculitis,  Pyoderma  gangrenosum,  Prurigo  nodularis, 
generalized  lichen  planus,  resistant  alopecia  universalis,  sarcoidosis,  psoriasis, 
Darrier’s disease, fast spreading vitiligo, airborne contact dermatitis4.
The  auto  immune  vesiculo  bullous  diseases  are  a  heterogenous  group  of 
diseases.  They  are  classified  on  the  basis  of  their  clinical,  histopathological  and 
immuno pathological features. They can be broadly classified histopathologically into 
epidermal and sub-epidermal blistering dermatoses.Though these disorders are rare in 
general population, for a given patient the impact of the diseases on the quality of the 
life can be devastating. The severity is often variable and the course is unpredictable 
and may even be fatal.
Pemphigus  is  the  commonest  autoimmune  vesiculobullous  disorder  of  the 
Indian subcontinent5. The main treatment for pemphigus lies in using corticosteroids 
and other similar  drugs which do help the patient  to recover from the disease but 
whenever an attempt is made to withdraw the drugs the disease tends to became active 
again. Long term use of these drugs lead to some serious side effects.
The  Dexamethasone  cyclophosphamide  pulse  therapy  pioneered  by 
Dr.Pasricha et al consists of giving dexamethasone and cyclophosphamide in a very 
large doses on three consecutive days and repeated at fixed 28 days interval. In this 
method these drugs are claimed to knock out the disease process so that the patient 
recovers  completely  while  the  side  effects  are  very  much  reduced  and  almost 
insignificant6.  It  is  claimed that  there  is  almost  no risk of a relapse or recurrence 
provided the treatment has been taken strictly as per the recommendations7.
With the ever increasing use of DCP pulse therapy in dermatology there is an 
increasing necessity for studies to evaluate its efficacy and side effect profile, and this 
study is an attempt in that direction.
REVIEW OF LITERATURE
HISTORICAL ASPECTS
 1953  -   Walter lever distinguished Pemphigus from Pemphigoid8
 1964 -  Beutner  and  Forder  discovered  circulatory  antibodies  against  cell 
surface of  Keratinocytes from the sera of Pemphigus patients 9
 1969 -  Kourtz  &  cohn10 to  prevent  renal  allograft  rejection-infused 
methylpredrisolene & heparin & actinomycin-D.
 1970 -  Coburg  et  al11 –  prednisolone  pulse  therapy  for  renal  allograft 
rejection.
 1971 -  Bell  et  al12 –  prednisolone  pulse  therapy  along  with 
immunosupressants for renal transplantation.
 1972 - Fedusca et al13 – first to use the word “pulse” for giving a high dose 
of methyl prednisolone intravenously for preventing renal allograft rejection.
 1976 - Cathcart et al14 – first to use pulse therapy – 1g Methylprednisolone 
in diffuse proliferative lupus nephritis.
 1981 -  Liebling  et  al15 –  first  to  use  methyl  Prednisolone  pulse  for 
rheumatoid arthritis.
 1981 - Dr.pasricha et al – Dexamethasone pulse therapy for Reiter’s disease.
 1982 - Johnson & Lagarus16 – first among the foreign workers to use the 
pulse  mode  of  therapy  successfully  in  a  dermatologic  disorder  –  methyl 
prednisolone pulse therapy for pyoderma gangrenosum.
 1982 - Synder et al17 – methyl prednisolone pulse therapy for treating drug 
induced lichen planus.
 1982 - Parischa et al Dexamethasone1 Cyclophosphamide pulse therapy for 
autoimmune vesiculo bullous disorder.18
The term Pemphigus refers to a group of autoimmune blistering disease of 
skin and mucous membranes that are characterized histologically by intra epidermal 
blisters  due  to  acantholysis  and  immuno  pathologically  by  in  vivo  bound  and 
circulating IgG directed against cell surface of keratinocytes.
Pemphigus  is  derived from the Greek word,  “Pemphix” meaning blister  or 
bubble19.
Types of Pemphigus:-
1. Pemphigus Vulgaris
Variant : pemphigus vegetans
2. Pemphigus foliaceus
Variant : pemphigus herpetiformis
Variant : pemphigus erythematosus
3. Induced pemphigus (Drugs, radiotherapy, thermal burns, diet)
4. Intercellular IgA dermatosis
5. Paraneoplastic pemphigus
Epidemiology :-
        The epidemiological aspects are covered below.
Disease Incidence Geographic pattern Age M:F HLA association
Pemphigus 
vulgaris & 
vegetans
About 1.3 
million/year
Higher in jews and 
people of 
Mediterranean origin
Middle 
age
M=F DR4(subtype) DQ1, 
DQB1,0503, 
DRB1(0402)
Pemphigus 
foliaceus/ 
erythematosus
0.3 cases per 
million per 
year
Higher in Brazil, 
Finland and Tunisia
Middle 
age
M=F
Fogo 
selvagum
3.4% on 
endemic 
areas of 
Brazil20
Endemic around the 
rivers of Brazil
Children 
& young 
adults
M=F DR1
In  an  Indian  study  by  Arya  et  al21,  pemphigus  vulgaris  was  the  commonest 
vesiculobullous  disease  comprising  61.4%  of  the  cases  studied  followed  by 
pemphigus foliaceus.  In the study by K.K.Das et al22,  pemphigus vulgaris was the 
commonest comprising 40.8% of the cases studied.
Etiopathogenesis :-
Disease Antibody 
Isotype
Target 
antigen
Antigen 
KDa
Epitope Location
Pemphigus 
vulgaris/vegetans
IgG(few 
IgM, 
IgA)
Desmoglein3
Desmoglein1
130KDa
160KDa
Amino 
terminal of 
extracellular 
domain
Desmosome
Pemphigus 
foliaceus/ 
erythematosus
IgG Desmoglein1 160KDa ,, ,,
IgA Pemphigus IgA1 Desmocollin1 - Desmosome
Fogo selvagum IgG Desmoglein1 160KDa Amino 
terminal of 
extracellular 
domain
Desmosome
Paraneoplastic 
Pemphigus
IgG Plakins 
(desmoplakin, 
envoplakin, 
BP230, 
periplakin) 
250KDa, 
210KDa, 
190KDa, 
500KDa
   
Various
Desmosomes, 
BMZ; 
Stratified, 
simple and 
transitional 
epithelia.
Clinical Features:-
Disease Cutaneous 
distribution
Mucosal 
involvement
Pattern  of  skin 
lesions
Scarring Disease 
association
Pemphigus 
vulgaris
Scalp, face 
flexures may 
be 
generalized
Common 
Oropharynx,
conjunctiva 
genitalia
Flaccid blisters, 
erosions show no 
tendency to heal, 
nikolsky sign      & 
bulla spread sign 
+ve, flexural 
vegetations
-
Other  auto 
immune disease,
Thymoma,  rarely 
bullous 
pemphigoid.  may 
evolve  into 
P.Foliaceus & vice 
versa.
Pemphigus 
Vegetans
Flexural Oral Vesicles,   pustules, 
        erosions, 
vegetating plaques
  
-
      
-
Pemphigus 
Foliceus
Scalp,face,ches
t,upperback(se
borrheic) may 
be generalized
- Scaly papules,
crusted erosions,
erythroderma
- -
Endemic 
pemphigus 
foliaceus
Head,neck 
generalized
Uncommon Flaccid blisters,
erosions,verrucous 
lesions,erythroderma
- -
Disease Cutaneous 
distribution
Mucosal 
involvement
Pattern  of  skin 
lesions
Scarring Disease 
association
Intercellular 
IgA 
dermatosis
Axillae, 
groins,  face, 
scalp, 
proximal 
limbs
Uncommon Flaccid  pustules
Annular  or  circinate 
configuration 
    -
IgA  monoclonal 
gammopathy.
Paraneoplasti
c pemphigus
Upper body, 
Palmo-
plantar
Severe 
mucositis
Polymorphous, 
Bullae,  erosions, 
‘target lesions’ 
     +
Lympho
proliferative 
disease, 
castleman’s,  other 
malignancies
Diagnosis:
The diagnosis can be made on the basis of clinical criteria and  by
1. Tzanck smear :-
Rapid preliminary test used in the diagnosis of blistering diseases. A smear is 
made from the floor of a freshly opened vesicle. It is allowed to dry and flooded with 
equal quantity of water and Giemsa (or) Leishman’s stain. After 30-40 seconds, the 
slide is rinsed, air-dried and examined for acantholytic cells.
Acantholytic cell :
An acantholytic cell is rounded cell with an enlarged nucleus with peripheral 
condensation of chromatin and prominent nucleoli. There is a perinuclear halo, with 
the peripheral parts of the cell staining more darkly. In older cells the nucleus may be 
pyknotic.
In  pemphigus  vulgaris  and  vegetans  typical,rounded  acantholytic  cells  are 
seen. In pemphigus foliaceus and pemphigus erythematosus, cells tend to be cuboidal, 
with  a  small  nucleus  and  more  prominent  cytoplasm.  keratohyaline  granules  and 
evidence  of  keratinisation  may  be  seen.  Occasional  multinucleated  cells  may  be 
seen.23 
2. Histopathology:
 Pemphigus vulgaris:-
A small early vesicle is preferable. Scalpel biopsy of the intact blister 
should be done. If punch biopsy is to be done, the lesion should be frozen by 
refrigerant spray. If no new blister is seen, an old one may be moved to the 
neighbouring skin by finger. The new cleavage reveals early specific changes.
Early lesions show eosinophilic spongiosis in the lower epidermis. This is the 
manisfestation of acantholysis, rather than true spongiosis. Developed lesions show 
clefts and supra basal blisters. Acantholysis extends to the adnexal structures.
The basal keratinocytes are detached from each other, but remain attached to 
the  basement  membrane,  because  the  hemidesmosomes  are  intact.  This  gives  an 
appearance of “row of tomb stones”.
As the blister  ages,  a  mixed inflammatory infiltrate  appears in the dermis. 
There may be epidermal downgrowth or villi.
 Pemphigus vegetans :
o Neumann type : 
Early  lesions  have  the  same  histopathology  as  pemphigus 
vulgaris.  Later  there  is  formation  of  villi  and  verrucous  epidermal  hyperplasia. 
Eosinophilic spongiosis and eosinophilic pustules are present. Acantholysis may be 
absent in older lesions.
o Hallopeau type : 
Early lesions have suprabasal clefts  with plenty of eosinophilis.   There are 
more eosinophilic abscesses than Neumann type.24
 Pemphigus foliaceus :
There is acantholysis  in the granular layer,  leading to subcorneal  cleft  and 
detachment of stratum corneum. The number of acantholytic cells is small. There may 
be eosinophilic spongiosis. Dyskeratotic granular keratinocytes are diagnostic.
 Pemphigus erythematosus :
Histology similar to pemphigus foliaceus. Interface dermatitis may be seen in 
rare cases.25
 IgA pemphigus :
o SPD type : There are subcorneal vesiculo pustules with minimal acantholysis.
o IEN type : Has intra epidermal vesiculo pustules with neutrophils.
 Paraneoplastic pemphigus :
Variable.  EMF-like,  LP-like,  pemphigus-like and Bullous pemphigoid-like 
features may be seen. PNP may present with lichenoid interface dermatitis without 
acantholysis26.
3. Direct Immunofluorescence:
 A 3-4mm punch biopsy from the inflamed, but unblistered   
perilesional skin is preferred.
 If there is a delay of more than 24 hrs before processing, the specimen  
should be kept in Michel’s medium, which contains 
                5% Ammonium sulphate 
                Magnesium sulphate
                N-Ethyl maleimide(K+ inhibitor)
                Citrate buffer (PH 7.25)
 Specimens may be kept in Michel’s medium for 2 weeks at room 
temperature and for several weeks in refrigerator.
 While processing, the specimen is washed, embedded in OCT (Optimized 
Cutting Temperature) compound, and snap frozen.6µ sections are made, 
and incubated  with anti human IgG, IgM, IgA and C3,which are tagged 
with  fluroscein  isothiocyanate.  Sections  are  visualized  in  fluorescent 
microscope27.
DIF Patterns
1. Pemphigus vulgaris
• Squamous intercellular IgG in upto 100%28 , in a chicken wire pattern
• DIF   remains  positive  for  many  years  after  the  clinical  disease  has 
subsided29.
• False positive tests may be seen in in spongiotic dermatitis,  psoriasis and 
insulation of serum.
2. Pemphigus vegetans
Squamous intercellular IgG present in all reported cases30.
3. Pemphigus foliaceus
Two patterns have been described commonly, full thickness squamous 
intercellular IgG is seen. Rarely IgG may be localized to the upper layers31.
4. Pemphigus erythematosus
Squamous intercellular IgG seen in >75% of cases, along with deposits 
of IgM (positive lupus band) in the DEJ.
5. Ig A Pemphigus
Reveals  squamous intercellular  IgA throughout  the epidermis.  Complement 
and other Immunoglobulins are usually absent. some cases show both IgA and 
IgG
4. Indirect immunofluorescence:
IIF is a semiquantitative procedure in which double immunolabelling 
is  done  to  evaluate  the  presence  and  titre  of  circulating  antibodies,  or  to 
specifically localize an antigen in the skin.
Procedure
The serum is serially diluted. The substrates most commonly used are 
 Monkey esophagus – pemphigus vulgaris32 
 Guinea pig esophagus – pemphigus foliaceus33
 Human salt split skin – subepidermal blistering diseases 
 Murine bladder epithelium – paraneoplastic pemphigus
The  serially  diluted  serum  is  incubated  with  the  substrate  for  30  mins  at  room 
temperature and washed. Antibodies bound to the substrate are detected by incubation 
with FITC-labelled goat antihuman IgA or IgG.
IIF PATTERNS
1. Pemphigus vulgaris
>80% have circulating anti cell surface IgG34. there is a positive, but 
imperfect  correlation  between  the  antibody  titre  and  disease  activity35 in 
pemphigus vulgaris and pemphigus foliaceus.
2. Pemphigus foliaceus
Squamous intercellular IgG deposits seen in 80 – 90% of cases.
3. Pemphigus erythematosus
Using monkey esophagus, IIF reveals ICS deposits of IgG  in 80% of cases ANA is 
positive in 30 – 80% of cases.
4. IgA pemphigus 
Positive in less than 50% of  cases.
5. Paraneoplastic pemphigus 
Circulating antibodies that bind to rat bladder  epithelium is seen in all 
cases.  Immunoblotting  and  immunoprecipitation  are  more  sensitive  and 
specific, and at a minimum , antibodies to envoplakin and periplakin should be 
demonstrated .
OTHER DIAGNOSTIC METHODS
ELISA
In pemphigus, antigen specific ELISA has been shown to be more sensitive 
and to correlate with disease activity better than IIF. 36
Immunoperoxidase  methods  have  roughly  the  same  sensitivity  as 
immunofluorescence studies.
Immunoprecipitation and Immunoblotting 
They detect antigens as protein bands of diiferent molecular weights separated 
by  electrophoresis.  Immunoblotting  requires  denaturation  of  substrates,  whereas 
immunoprecipitation  does  not.  The  former  recognizes  antibodies  against  linear 
epitopes   while  the  latter  recognizes  antibodies  against  conformational  epitopes. 
Immunoblost is easier because immunoprecipitation requires radiolabelling.
                                    
  
PULSE THERAPY REGIMENS
         The introduction of   Dexamethosone-Cyclophosphamide Pulse (DCP ) therapy 
for  the pemphigus group of disorders by Pasricha et al at the All India Institute of 
Medical Sciences,New Delhi,in 1986 has revolutionized the therapy for pemphigus 37 
The Standard DCP Regimen38 : 
                       The standard DCP Regimen Consists of 4 phases.
Phase  I  :  In  this  Phase,100mg  of  Dexamethasone  dissolved  in  500ml  of  5% 
Dextrose,  given as a slow intravenous infusion over two hours and repeated on 3 
consecutive days, combined with 500mg Cyclophosphamide in the same infusion on 
any one of these three days but preferably on the second day. This constitutes one 
DCP; such DCP are to be repeated at exactly 4-weeks interval counted from the 1st 
day  of  each  DCP;  in  between  the  DCPs  the  patient  receives  only  50mg 
Cyclophosphamide per day orally;The period during which the patient continues to 
develop clinical lesions in between the two DCPs till the patient achieves complete 
clinical remission is designated as Phase I ;The duration of the Phase varies widely in 
different patients.
Phase II : After the patient achieves clinical remission, the DCP is given at 4 weeks 
interval and 50mg daily oral dose of  Cyclophosphamide are continued for next 6 
months;  This is called Phase  II.This phase is retrospectively calculated;
Phase III: If the patient continues to be in clinical remissions during Phase II, the 
DCPs are stopped but the oral dose 50mg Cyclophosphamide per day is continued for 
next 1 year .This is called Phase III.
Phase  IV:  If  the  patient  still  continues  to  be  in  remission,  even  this  dose  of 
cyclophosphamide is withdrawn and the patient is followed up without any treatment 
to look for any tendency for a relapse(The post treatment follow up period);This is 
called Phase IV and can be as long as possible .
          The dosage of dexamethasone pulse infusion was fixed at 100mg because of the 
commercial availability of the 100mg pack and the dose of Cyclophosphamide for the 
pulse was fixed at 50 mg for the sake of convenience and to have reasonably effective 
dose without producing serious side effects.
          The Oral Dose of Cyclophosphamide was fixed at 50mg per day because this 
dose is almost completely free from side effects, it does not produce leukopenia and 
thus the patient does not require any monitoring on a day-to-day basis.
          The time interval of 4 weeks between the two DCPs was also arbitrary and 
selected for the sake of convenience; but later on it was realised that it is necessary to 
administer  the  next  pulse  before  the  immunocompetent  cells  responsible  for 
producing the auto antibodies start proliferating again.
MECHANISM OF ACTION
                    Exact mechanism of action not known. It is presumed that supra 
pharmacologic doses of dexamethasone and cyclophosphamide knock down the auto 
antibody producing cells and when such doses are repeated at regular intervals before 
these cells have a chance to proliferate and regenerate themselves more and more of 
such cells are being progressively destroyed and a stage can possibly be reached when 
all such cells have been eliminated can virtually inactivated; At that stage there would 
be no further risk of developing a relapse39.
                   Dexamethasone  is  a  potent,  long acting  steroid  with  specific 
glucocorticoid and nil mineralocorticoid activity with a half life more than 36 hours. 
The high potency is attributed to its high affinity for the glucocorticoid receptor and 
long half life. Its metabolized by hepatic microsomal enzymes. It acts by inhibiting 
transcription factors  AP-1, NF-kB  while increasing Ik-Bα which is an inhibitor of 
NF-kB. Along with suppression of pro inflammatory cytokines this forms the crux of 
its action.40  
                     Cyclophosphamide is a pro-drug that is converted by hepatic microsomal 
enzymes into 4-Hydroxy cyclophosphamide.The half life is between 3 to 10 hours .It 
is classified as an alkylating agent. These agents are most active in the resting phase 
of the cells. These drugs are cell cycle non-specific 41.
MODIFICATION OF THE STANDARD DCP  REGIMEN 42
1. If the patient is already receiving a daily dose of some corticosteroid and/or an 
immunosuppressive  drug,the  same  dose  is  continued  and  the  DCP  therapy  is 
strated till  the patient attains complete clinical  remission.after  this,daily dose is 
progressively reduced at the rate of 10mg prednisolone or 1mg of betamethasone/
dexamethasone at the time of each pulse till the daily dose of corticosteroid and 
the immunosuppressive drug is completely withdrawn and the patient is receiving 
only  50mg  cyclophosphamide  per  day  in  between  the  DCPs  .The  patient  is 
considered to be Phase I as long as the patient is receiving any additional dose of 
corticosteroid/immunosuppressive drug even if he is in clinical remission
2. In  case  the  patient  has  a  concomitant  disease  such  as  diabetes 
mellitus,hypertension,  peptic  ulceration,  tuberculosis,or  pyogenic,candidial  or 
dermatophytic  infection  the  treatment  of  the  concomitant  disease  is  to  be 
continued/  started  simultaneously  without  interrupting  the  DCP  therapy.The 
patients having diabetes mellitus are to be given 8 units of insulin added to each 
bottle of 500ml glucose and this should be in addition to the treatment given to 
control the diabetes. In case however, the patient develops herpes simplex,herpes 
zoster or any other infection which can/has spread dangerously, the pulse therapy 
has to be interrupted temporarily till the viral infection has been controlled.
3. In case the patient has a cardiac,renal,heptic or neurologic problem,the opinion of 
the corresponding specialist must be obtained to ascertain that the pulse therapy 
will not advesely affect the other disease. This is especially necessary in patients 
having cardiac arrhythmias.
4. In case the skin lesions or mucosal ulcers are heavily infected and there is a risk of 
dissemination of the infection and  toxaemia,the institution of the pulse therapy 
can be delayed till the infection has been controlled  or the first few pulses can be 
given with dexamethasone alone(without cyclophosphamide).
5. Unmarried patients or those who have not yet completed their family and want to 
have  more  children,should  be  treated  with  only  dexamethasone  pulses  giving 
100mg  of  dexamethasone  on  3  consecutive  days,  along  with  50mg 
cyclophosphamide orally per day.  The high dose of cyclophosphamide is to be 
withheld  because  this  dose  likely  to  lead  to  azoospermia/amenorrhoea  and 
therefore infertility.  The dexamethasone pulse therapy will be able to make the 
patient recover from the disease but there is an increased chance of developing  a 
relapse at some time in the future. The patient should complete  the treatment as in 
the  standard  DCP  regimen(without  cyclophosphamide  pulses)  and  after  the 
treatment has completed and the drugs have been withdrawn the patient should be 
advised to get married and have children. In case there is a relapse at any time in 
the future,  the standard  DCP therapy regimen can be administered to achieve 
permanent remission.
6. Patients undergoing DCP therapy are routinely advised to practice contraception 
during  the  period  of  the  treatment  because  corticosteroids   and 
immunosuppressive  drugs  are  well  known  to  lead  to  foetal  developmental 
abnormalities . In case however, a pregnant patient develops pemphigus,the pulse 
therapy has to be withheld till the baby is delivered and weaned off. The patient 
can be treated with daily doses of corticosteroids using as small a dose as possible 
to control the disease. If pulse has to be used, it should only be a dexamethasone 
pulse  and no  cyclophosphamide  or  any  other  immunosuppressive  drug,  and  a 
written advice/permission from the obstetrician must be obtained.
After the patient has delivered the baby and the child put on artificial 
feed(weaned)  the  pulse  therapy  can  be  started  as  per  the  criteria  outlined 
previously.
7. In case the patient is a child below the age of 12 years, the dose of dexamethasone 
in  the  pulse  should  be  reduced  to  50mg,  and  the  daily  dose  of  oral 
cyclophosphamide  should  be  reduced  to  25mg  per  day.  The  large  dose  of 
cyclophosphamide in the pulse is not to be given, because of the possibility of 
azoopermia in the males and amenoorrhoea in the females.
8. In case the patients continues to have recurrences in between the DCPs and the 
duration of  Phase I seems to be getting unduly prolonged, the patient can be given 
additional dexamethasone pulses. An additional dexamethasone pulse consists of 
two doses of 100mg each administerd on 2 consecutive days  in between the two 
DCPs. Cyclophosphamide is not to be given with the additional dexamethasone 
pulses because too frequent administration of large doses of cyclophosphamide 
can lead to excessive immunosuppression and make the patient  more prone to 
develop severe pyogenic or  candidial infections.
9. The patients  who show a tendency to  develop recurrences  even earlier  than 2 
weeks after the DCPs  can be given a daily dose of corticosteroids in addition to 
the 4weekly DCPs with/without additional dexamethasone  pulses. The daily dose 
of corticosteroids should  be adjusted to a level  which can control the activity of 
the disease. After the patient attains complete clinical remission. The daily dose of 
corticosteroid should be withdrawn in a step-wise manner at the time of giving the 
DCPs and the additional dexamethasone pulses. Phase II should be considered to 
have begun only after the daily dose of corticosteroid  as well as the additional 
dexamethasone  pulses  have  been  completely  withdrawn  and  the  patient   is 
receiving only DCPs given at 4-weekly intervals along with the 50mg daily oral 
dose of cyclophosphamide.
10. Some  workers  have  used  azathioprine  in  a  dose  of  50-100mg  along  with 
dexamethasone in place of cyclophosphamide particularly in unmarried patients 
who have not yet completed their family. But azathioprine is expensive and it is 
potentially hepatotoxic.
INDICATIONS AND CONTRAINDICATIONS:
                 Since the risk-reward ratio of DCP therapy is claimed to be favourable 
and because it is  said to cure pemphigus it is justified to treat all pemphigus cases 
with DCP irrespective of the severity of the disease43 . 
                                                  There are almost no contraindications. The only  
contraindication for pulse therapy is pregnancy or if the patient is a lactating mother. 
This is also not an absolute contraindications. Pulse therapy is only to be postponed 
till the patient has delivered her baby and stopped feeding the child.
SIDE EFFECTS:
ATTRIBUTABLE TO CORTICOSTEROIDS:
INCREASE IN BODY WEIGHT: 
DCP regimen does not lead to an increase in the body weight inspite of the 
high dose of corticosteroids used during the DCP therapy.44   Pasricha et al, from their 
observations showed that some patients who showed an increase in the body weight 
during the treatment but most of these patients were those who were also receiving a 
daily dose of steroids and/ or additional dexamethasone pulses
INFECTIONS :
 a.Pyodermic infections:
                                 High incidence of bacterial infection during  Phase I may actually 
be due to the presence of skin ulcers rather than the administration of DCP .45
b.Candidosis:
The incidence of candidial infection in the mouth was also extremely high in 
patients having oral ulcers.
As in the case of bacterial infection  of the skin, the candidial infection in the 
oral cavity also seems to be related more to the presence of ulceration in the mouth 
rather than the  DCP therapy.45
c. Dermatophytosis:
Observed in only a few patients especially during Phase I and II but also in the 
subsequent Phases, and most of the times it is not different from the dermatophytic 
infection observed in other individual.45   
d.Tuberculosis:
Reactivation  of  the  tuberculosis  during  the  DCP  therapy  may  occur  very 
rarely.
e.Viral infection:
Patients developing varicella / herpes zoster while  receiving the DCP therapy, 
may  be   kept  under  observation  and  even  treated  with  acyclovir  and  the  pulse 
administered at the predestined time if there is a reasonable certainity that the viral 
infection will not spread46 .Corticosteroid treatment has been suggested as a risk factor 
for developing Kaposi’s varicelliform eruption,47  in addition to   pemphigus foliaceus 
itself.48
DIABETES MELLITUS:
The incidence of diabetes mellitus in patients receiving DCP therapy has been 
estimated to be 2%. A diabetic state caused by the administration of corticosteroids is 
likely to revert back to the normal state after the corticosteroids are withdrawn49.
HYPERTENSION:
The  incidence  of  hypertension  in  patients  receiving  DCP therapy  is  fairly 
low50.
CATARACT:
                  May be detected  during all the 4 phases of the DCP regimen. Almost all  
patients however are old and could have developed cataract even without the DCP 
regimen.  The risk of developing premature cataract  consequent  to DCP therapy is 
practically nil 51.
ACID PEPTIC DISEASE:
More  often  observed  in  the  patients  who  were  receiving  a  daily  dose  of 
steroids. Rare in DCP therapy .51
ASEPTIC NECROSIS OF THE BONES:
A  well  recognized  complication  of  high  dose  corticosteroid  therapy.  In  a 
study  by  Pasricha  et  al  only  one  patient  out  of  250  patients  developed  this 
complication.
LEUKOPENIA:
Rare one. Transient and  recovers without any special treatment.
GENERAL WEAKNESS AND LETHARGY:
Observed during first few pulses, this side effect tends to disappear as the 
treatment with the DCP regimen is continued .51
PITUTARY ADRENAL AXIS SUPPRESSION:
Occurs in about half of the patient who receive DCP therapy for pemphigus. 
These  patients  probably  do  not  require  routine  replacement  therapy  with 
corticosteroid but may need supplementation during periods of stress52.
MISCELLANEOUS:
 Hiccups53
 Transient puffiness, edema, Joint pain and muscle pain54.
 Hirsutism, facial flushing55  ,diarrhea.
ATTRIBUTABLE TO CYCLOPHOSPHAMIDE:
The main side effects are  leukopenia, hematuria, gonadal failure, generalized 
pigmentation and hair loss56.
HEMATURIA:
Well known complication of cyclophosphamide  therapy due to the stagnation 
of acrolein in the urinary bladder, a metabolite of cyclophosphamide.  In the study of 
Pasricha  et  al  only  2%  of  the  patients  developed  hemorrhagic  cystitis. 
Cyclophosphamide should be taken in the morning so that major part of the drug is 
excreted out during the day and there is no accumulation of the drug in the bladder 
during the night time . Hemorrhagic cystitis usually occurs after a cumulative dose of 
85gm of  cyclophosphamide  57. Cystitis can be reduced in intensity or prevented by 
parenteral administration of MESNA- a sulfhydryl compound that readily reacts with 
acrolein in the acid environment of the urinary tract.58
GONADAL FAILURE:
Cyclophosphamide interferes with oogenesis and spermatogenesis and it may 
cause infertility in both sexes. Development of sterility appears to depend on the dose 
of cyclophosphamide , duration of therapy and  the state of gonadal function at the 
time of treatment.            
Amenorrhoea  occurs in about 50% of the female patients treated with DCP 
regimen 59; In the study by McDermott et al the incidence of premenopausal ovarian 
failure was 54% and the incidence of pre mature menopause (occurring before 40 
years  of  age)  was  41%  after  treatment  with  cyclophosphamide  pulse  therapy.60 
Cyclophosphamide induced sterility may be irreversible in some patients61.  Incidence 
of azoospermia is estimated to be same as amenorrhoea in females that is 50%62
PIGMENTATION:
General  darkening  of  complexion63 and  a  peculiar  pattern  of  nail 
pigmentation64 have been documented .
HAIR LOSS:
Diffuse hair loss is observed in a very high proportion of the patients mainly 
during   Phase  I  and  Phase  II;   Anagen  defluvium  is  a  known  complication  of 
cyclophosphamide therapy.65
Leucopenia and Thrombocytopenia:  rare65
AIM OF THE STUDY
AIM OF THE STUDY
This study of Dexamethasone Cyclophosphamide  Pulse therapy in Pemphigus 
patients was undertaken
1. To find out the clinical efficacy of DCP therapy in Pemphigus patients.
2. To find out the various side effects of the regimen. 
MATERIALS AND   METHODS
MATERIALS AND METHODS
The material  for this  study was from the patients  attending the skin OPD, 
Government  Rajaji  Hospital,  Madurai  Medical  College,  Madurai  with  pemphigus, 
during the period of June 2005 – June 2007.
Inclusion Criteria:
1. Above 18 years of age
2. The  patients  with  pemphigus  vulgaris,  pemphigus  foliaceus,  pemphigus 
erythematosus registered during the period from June 2005 –June 2007 and whose 
diagnosis  was  confirmed  by  Histopathological  examination  and  Direct 
immunofluorescence. 
Exclusion Criteria :
1. Age below 18 years.
2. Uncontrolled diabetes mellitus/ Hypertension. However diabetic and hypertensive 
patients were included, if their disease was under control with appropriate therapy. 
The routine antidiabetic and antihypertensive drugs were continued in the same 
dose along with DCP. However six units of insulin was added to counter the effect 
of 5% dextrose in diabetic patients.
3. Severe systemic diseases where high dose steroids are contra-indicated.
4. Pregnant and lactating mothers.
5. Patients on long term systemic steroids therapy.
6. Pemphigus patients in whom the diagnosis could not be confirmed by DIF.
7. Patients who had not completed their family.
After applying the criteria mentioned above, 26 cases of pemphigus enrolled 
for pulse therapy and followed up from June 2005 – June 2007. After their informed 
consent they were hospitalized and thorough general,  systemic  and dermatological 
examinations were done. Relevant Baseline investigations  like complete haemogram, 
routine  blood  biochemistry,  urine  examination,  electro-cardiography,  chest  X-ray, 
semen analysis, baseline Fitzpatrick skin typing were done.
Dexamethasone  Cyclophospamide  pulse  therapy  was  administered  to  each 
patient, strictly adhering to the prescribed guidelines. Due importance was given to 
patient education regarding the disease process and the treatment regimen.
              During every pulse, complete blood count, urine analysis especially for red 
blood  cells,  electrocardiogram,  blood  sugar,  blood  urea,  serum  electrolytes,  liver 
function  tests,  stool  examination  for  occult  blood,  ophthalmic  examination  for 
cataract, blood pressure recording and weight charting were done.
                                    OBSERVATIONS & RESULTS
OBSERVATIONS AND RESULTS
In this study, 26 cases of Pemphigus patients from the outpatient Department 
of  Dermatology,  Government  Rajaji  Hospital,  Madurai  were  treated  with 
Dexamethasone Cyclophosphamide pulse therapy and observed during the period of 
June 2005 – June 2007; The following observations were made.
Type of Pemphigus:
Of  the  26  pemphigus  patients  18(70%)  patients  had  pemphigus  vulgaris, 
7(26%)  patients  had  pemphigus  foliaceus,  and  1  (4%)  patient  had  pemphigus 
erythematosus.  Thus  pemphigus  vulgaris  is  by  far  the  most  predominant  type  of 
pemphigus requiring DCP therapy.
                          Table I
Disease No. of patients Percentage (%)
Pemphigus Vulgaris 18 70
Pemphigus Foliaceus 7 26
Pemphigus Erythematosus 1 4
Pemphigus vulgaris
Pemphigus foliaceus
Pemphigus erythematosus
Sex ratio:
In our study 16 patients were females while 10 patients were males. In our 
study the male: female ratio was 1:1.6
Table II
Type of Pemphigus Total Male Female M:F
Pemphigus Vulgaris(PVul) 18 6 12 6:12
Pemphigus Foliaceus(PF) 7 4 3 4:3
Pemphigus Erythematosus(PE) 1 - 1 0:1
Total 26 10 16 5:8
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Age  Distribution:
The age at recruitment in various types of pemphigus is shown in Table III. 
Most of the patients were between the ages of 20 to 60 years when the disease started.
    Table III
Age at 
onset(years)
Pemphigus 
Vulgaris
Pemphigus 
Foliaceus
Pemphigus 
Erythematosus
Total
<20 - 1 - 1(4%)
20 – 40 9 2 1 12(46%)
40 – 60 9 4 - 13(50%)
>60 - - - -
0
1
2
3
4
5
6
7
8
9
Pvul PF PE
<20 years
20 – 40 years
40 – 60 years
>60 years
Distribution of lesions
Involvement of skin and mucous membrane:
In 9 patients, the disease was limited to skin only. In the remaining 17 patients 
both the skin and the mucous membranes were involved.
Table IV
Pemphigus 
Vulgaris
Pemphigus 
Foliaceus
Pemphigus 
Erythematosus
Number 
of 
patients
Percentage
(%)
Involvement 2 7 1 10 39
of skin only
Involvement 
of both skin 
and  mucous 
membranes. 
16 0 - 16 61
Table V
Order  of 
involvement 
Pemphigus 
Vulgaris
Pemphigus 
Foliaceus
Pemphigus 
Erythematosus
Number 
of 
patients
Percentage
(%)
Mucosa first 14 - - 14 54
Skin first 2 7 1 10 38
Simultaneous 
involvement
2 - - 2 8
The mucosal involvement was severe in all patients with pemphigus vulgaris 
and preceded the skin lesions by a mean duration of 2 months. A detailed analysis of 
the involvement of various mucous membrane in 26 patients revealed involvement of 
oral mucosa in 18 patients, nasal mucosa in 3 patients, genital mucosa in 5 patients, 
conjunctival mucosa in 1 patient and anal mucosa in 1 patient. 3 patients had palms 
and soles involvement as their presenting feature.
Table VI
Mucous membrane Number of patients Percentage (%)
Oral mucosa 18 70
Genital mucosa 5 19
Nasal mucosa 3 12
Conjunctival mucosa 1 4
Anal mucosa 1 4
RESPONSE TO THE DCP REGIMEN
Adherence:
Of the 26 patients, only 3 (12%) were lost to follow up. Strict adherence to the 
regimen was offered by all the patients who completed the study.
Table VII
Total patients 26
  On DCP 20 (76%)
  Left out 3 (12%)
  Died 3(12%)
Patients lost to follow up:
     A total  of  3  patients  (12%) could  not  continue  the  treatment  for  the 
following reasons.
Table VIII
Presumed reason Number of Patients
Due to long distance              2
Due to haemorrhagic cystitis              1
Cause of Death :
      A total  of 3 patients  died in our study.  All  the  deaths  were due to 
septicaemia.
Table IX
Disease Number of patients Cause of death Phase
Pemphigus vulgaris 2 Septicaemia I
Pemphigus foliaceus 1 Septicaemia I
Number of DCP required to achieve complete clinical remission :
                 Response to DCP regimen was gradual in our study but remission was 
achieved in all the treated patients.
        Table X
Number of DCP Pemphigus 
vulgaris
Pemphigus 
foliaceus 
Pemphigus 
erythematosus
Number  of 
Patients
      1-6         -     -     -      -
     7-12         -     -     -      -
    13-24        11     3     1      15
     25-36        5     -     -       -
   37-48        -     -     -      -
 The average number of pulses required to achieve remission in Pemphigus 
vulgaris and Pemphigus foliaceus was observed to be 20 and 16 respectively in our 
study.
Phase wise distribution of cases at the end of study period:
Out of the 26 patients, a total of 11 patients were in phase III, 7 patients were in phase 
IV, 2 patient relapsed during phase IV, 3 patients could not continue the treatment 
with us for a variety of reasons and 3 patients had died.
Table XI
Male Female Total
Phase I - - -
Phase II - - -
Phase III 3 8 11
Phase IV 4 3 7
Relapse rate :
Out  of  the  26 patients  2  patients  relapsed during phase IV.  These 2 patients  had 
persistent oral ulcers during phase I. There was no obvious cause for relapse. 
Side effects :
Table XII
Side effects Phase I Phase 
II
Phase 
III
Phase 
IV
Total Percentage 
(%)
Weight gain - 2 - - 2 8
Pyodermic infections 2 1 - - 3 12
Dermato phytosis 1 1 - - 2 8
Candidosis 2 1 - - 3 12
Kaposi’svaricelliform 
eruption
1 - - - 1 4
Hypertension - - - - - -
Diabetes mellitus 3 - - - 3 12
Catatract - - 1 1 2 8
Hematuria 1 - - - 1 4
Menstrual 
abnormalities
4 2 - - 6 38
Defective 
spermatogenesis
- - 3 4 7 70
Skin pigmentation 4 3 1 - 8 30
Nail changes 2 - - - 2 8
Diffuse hair loss 2 3 - - 5 20
Teeth loss - 1 - - 1 4
Bone pain 2 - - - 2 8
Periodontitis - 1 - - 1 4
Pedal edema 1 - - - 1 4
Hiccups 1 - - - 1 4
The following was a brief account of the side effects observed in our patients and the 
measures taken to deal with the side effects :
1. Weight gain :- {more than 10% of baseline body weight}
Out of the 26 patients 2 patients (8%)showed weight gain in phase II.
2. Infections :- 
 Pyodermic infections : 
In  our  study 3  patients  (12%)  showed  pyodermic  infections.  Gram 
stain,  culture  and  sensitivity  done  for  these  patients  which  showed 
staphylococcus  aureus.  These patients  were treated with appropriate  topical 
and systemic antibiotics.
 Dermatophytosis :
Dermatophytic infection of the skin was observed in 2 patients (8%) 
especially  during phase I  and II.  In these patients  extensive dermatophytic 
infection was noticed.
 Candidosis :
In our study oral candidosis was observed in 3 patients (12%) mainly 
during phase I and they are treated with topical anti candidal agents.
 Kaposi’s varicelliform eruption :
One  male  patient  with  Pemphigus  foliaceus  developed  vesicular 
eruption over the face during phase I, which was diagnosed to be Kaposi’s 
varicelliform eruption and confirmed by Tzanck smear and Histopathological 
examination. He was treated with oral acyclovir 200mg X 5 times a day for 7 
days and he recovered completely.
3. Diabetes mellitus :
During phase I, 3 patients were discovered to have diabetes mellitus. 
These patients were given appropriate treatment to control their disease and in 
addition each patient was given 8 units of insulin along with every bottle of 
500ml of 5 % dextrose used for the infusion.
4. Hypertension :
In  our  study  none  of  the  patient  developed  systemic  hypertension 
during or after DCP therapy. Only one patient had preexisting hypertension 
and his blood pressure was within normal limits with antihypertensive drugs.
5. Cataract :
Cataracts were detected in 2 patients (8%) in our study. These patients 
however were old and they were above 50 years  of age.  They could have 
developed cataract even without the DCP regimen. There was no patient who 
could be considered to have developed premature cataract.
6. Hematuria :
A 55 year old male patient who was administered DCP for pemphigus 
vulgaris  developed  hematuria  after  the  3rd pulse.  Cystoscopy  revealed  the 
presence of haemorrhagic  cystitis  confirming that  the hematuria  was being 
caused by cyclophosphamide. The cystitis subsided with oral intake of plenty 
of fluids. He, however was lost to follow up since then.
7. Menstrual abnormalities :
Out of the 16 female patients in our study, 6 patients (38%) developed 
amenorrhoea at the end of phase I. None of the patient regained her menstrual 
cycle after the cessation of pulse therapy. Ultrasound revealed ovarian atrophy 
in  2  patients.  One  patient  developed  menorrhagia  during  phase  I.  She 
responded  to  symptomatic  treatment  and  she  regained  her  normal  cycles 
during phase III.
8. Abnormalities of  spermatogenesis:
Defective spermatogenesis was observed in 7 patients (70%) out of 10 
male patients.  All patients showed more than 50% reduction in their sperm 
count. They also showed profound inhibition of sperm motility, however there 
were  no  significant  morphological  abnormalities.  These  changes  were 
observed mainly during phase III.
9. Pigmentation :
Generalized Pigmentation was observed in 8 patients (30%)
10. Diffuse Hair loss :
Diffuse loss of hair was seen in 5 patients (20%) mostly during phase I 
and II, when the patient was receiving high doses of cyclophosphamide. In all 
these patients the hair re-grew to their original profusion after the completion 
of  Pulse therapy.
11. Teeth loss :
A 35 year  old male patient  -   a case of pemphigus  foliaceus had a 
sudden unexplained loss of multiple teeth  at the end of phase I.
12. Osteoporosis :
2 female patients (8%) developed low back ache during pulse therapy. 
Their   X-ray showed osteoporotic changes of the spine.
13. Periodontitis :
Observed in  one patient which subsided with appropriate antibiotic therapy.
14. Hiccups :
One  patient  developed  intractable  hiccups   during  phase  I  and  he 
responded  well  to  chlorpromazine.  Then  he  was  put  on  prophylactic 
chlorpromazine, during subsequent pulses.
15. Nail changes :
Hyperpigmentation  of  nails  was observed in  2  patients  (8%) in  our 
study.
16. Other side effects :
 Several patients complained of generalized weakness, lethargy and lack of
desire  to do anything for 3 – 4 days  following each pulse which subsided 
during phase III.
 Transient puffiness of face was observed in few patients for 2 – 3 days after  each 
pulse which subsided without treatment.
DISCUSSION
DISCUSSION
     The study was conducted during the period of June 2005 – June 2007 at the 
Department of Dermatology , Government Rajaji Hospital, Madurai Medical College, 
Madurai.  26   Pemphigus  patients  were  treated  with  Dexamethasone 
Cyclophosphamide Pulse therapy during the period of study.
Case distribution :
Of the 26 patients who completed our study 18 patients (70%) had pemphigus 
vulgaris, 7 patients (26%) had pemphigus foliaceus,and 1 patient (4%) had pemphigus 
erythematosus .In the study by Pasricha et al out of 500 patients 89% had pemphigus 
vulgaris. However pemphigus foliaceus patients comprised only  6% . This may be 
due to geographic variations in the incidence pattern of these diseases or exclusion of 
pemphigus foliaceus by Pasricha et al in their study . 
Our Study
Pemphigus vulgaris
Pemphigus foliaceus
Pemphigus
erythematosus
Dr.Pasricha et al Study
Pvul
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pemphigus vegetans
Sex distribution :
In our study the male:female ratio was is 1:1.6. In the study by Pasricha et al 
the ratio was 1:1. The female preponderance in our study tends to reflect the overall 
sex distribution of pemphigus in our centre.32 cases of autoimmune bullous diseases 
were diagnosed in about 1,92,750 patients  who attended the skin OPD during the 
period of study and the male:female ratio was approximately 2:3. 
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Age Distribution:
Majority of our patients  (  96%) were between 21 – 60 years  of age.  This was in 
concordance with the study by Pasricha et al who recorded 88% in that age group.
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Involvement of the skin and mucous membrane:
Involvement Our study 
(%)
Pasricha et al (%)
Skin alone 37 27
Mucous membrane only - 25
Both skin and mucous 65 52.4
Our results were comparable with Pasricha et al study except that the skin is 
involved in some point of the course of the disease and none of our patients  had 
exclusive mucous membrane involvement whereas  25% had the same in Pasricha et 
al study.
Number of pulses required to achieve remission:
Number of DCP required Our 
study
(%)
Dr.Pasricha et al
(%)
1 – 6 - 66
7 – 12 - 9
13 – 24 75 13
25 – 36 25 3
37 – 48 - 1
In our study majority of patients (75%) required an average of 16 pulses to 
achieve remission whereas in the study by Pasricha et al even with 6 DCP they were 
able to achieve remission in 66% of patients. It is obvious that there is gross variation 
between these studies. Hence an universally acceptable  clinical  scoring or grading 
system to objectively assess the severity of the disease process and to monitor the 
clinical  progress  may allow for a fair  comparison between reports from different 
centres.  This is  particularly important  because Indirect  immunofluorescence  titres 
bear only an imperfect correlation with clinical activity66. 
                Simultaneous  multicentric  studies  are  another  possible  method to 
circumvent this problem. We also observed that the average number of DCP required 
to  achieve  remission  in  Pemphigus  vulgaris  (20)  is  higher  than  that  required  in 
Pemphigus foliaceus(16 ).
Patients lost  to follow up :
3 patients ( 12%) out of 26 patients did not complete our study. Out of these 3 
who were lost to follow up, inability to travel long distance was the reason in two 
cases and the development of hemorrhagic cystitis was the reason the other. In the 
study by Pasricha et al 16% of patients did not complete the study.
Cause of death :
3 out of  26 patient ( 11% )in our study died during the study period. All the 
deaths(100%)were attributed  to  septicaemia.  In  the study by Pasricha et  al  3% of 
patients died during the study period and the most common cause of death in his study 
also septicaemia. In the study by Royrenu et al study, 11% of patients died during the 
study period and the major cause of death was found to be septicaemia.
Relapse rate and cause of relapse : 
In  our  study  2  patients  (8%)  showed  relapse  in  phase  IV.  There  was  no 
attributable cause for their relapse. In Pasricha et al study 14% showed relapse mostly 
due to irregularity of pulses and incomplete phase II.   The lower rate of relapse (8% 
vs 14%) during phase IV in our study may be due to better adherence of our patients 
to the prescribed regimen. However, careful follow up of the patients for a longer 
period of time is essential to ascertain the efficacy of DCP as a curative treatment.
Side effects:
 Significant weight gain ( more than 10% from the baseline) was observed 
in 2 patients (8%) in our study whereas it was 3% in the study by Pasricha 
et  al  study.  Retention  of  sodium  and  water  could  be  the  possible 
explanation of weight gain.
 While Kaposi’s varicelliform eruption was observed in one patient a case 
of pemphigus foliaceus in our study, no such manifestation was observed 
by Pasricha et  al  and Roy renu et  al  in their  study.  However  Kaposi’s 
varicelliform eruption is one of the well  known complication of steroid 
therapy and pemphigus foliaceus itself.
 In  our  study  3  patients  (12%)  developed  diabetes  mellitus  whereas  in 
Pasricha et al study it was 1% only. The variation can be attributed to the 
small sample size of our study.
 Menstrual irregularities: Amenorrhoea was observed in 6 patients(38%) in 
our study, as compared to 50% in the study by Pasricha et al . None of the 
patients regained her menstrual cycle even after one year of cessation of 
the pulse therapy.
 Defective spermatogenesis was observed in 7 patients(70%) in our study. 
Count and motility were the parameters affected significantly.  Marginal 
recovery of spermatogenesis was observed in 5(72%) of the 7 patients. No 
improvement in spermatogenesis could be detected in the other two.
 Generalised  skin  pigmentation  was  observed in  8  patients(30%)  in  our 
study where as it was 1% in pasricha et al study. This disparity could be 
possibly due to the higher baseline pigmentation(Fitzpatrick skin type IV-
VI)  in  south  Indian  patients  as  compared  to  their  North  Indian 
counterparts.
 Sudden simultaneous unexplained loss of teeth was observed in one patient 
with  pemphigus  foliaceus  after  six  pulses  of  DCP.  There  was  no  pre 
existing  dental  pathology  that  could  be  held  responsible  for  this 
phenomenon.
 Osteoporosis was observed in 2 female patients(8%) in our study. It is a 
well known complication of high dose steroid therapy. Avascular necrosis, 
a rare complication noted in 0.4% of patients in the study by  Pasricha et al 
was not encountered in our study.
 
CONCLUSION
CONCLUSION
1) Pemphigus vulgaris is by far  the commonest epidermal autoimmune 
vesiculobullous disorder that  requires  Dexamethasone cyclophosphamide 
pulse therapy.
2) An overwhelming majority of patients requiring DCP for  Pemphigus are in 
the reproductive age group.
3) DCP significantly improves patient compliance by reducing the duration of 
hospital stay.
4) The average number of pulses required to achieve clinical remission is 
significantly higher than the figures mentioned in the available literature.
5) Septicaemia is the commonest cause of death in patients receiving DCP.
6) Metabolic side effects attributable to long term steroid therapy are 
significantly lower in patients treated with DCP.
7) An universally acceptable clinical grading of Pemphigus is needed to 
objectively assess the baseline severity and subsequent improvement. It would 
also allow for a fair comparison of the results reported by different centres.
8) Potentially irreversible gonadal suppression appears to be the most important 
side effect against which the benefits of DCP have to be weighed.
9) Ways and means to reduce the gonadal toxicity of DCP need to be explored, 
as DCP therapy is likely to stay as the treatment of choice in autoimmune 
vesiculobullous diseases.
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Figure 1: A case of pemphigus foliaceus before and after DCP
Figure 2:A case of  pemphigus vulgaris before and after DCP
Figure 3:  A  case of pemphigus foliaceus with kaposi's 
varicelliform    eruption
Figure 4: A case of  Pemphigus foliaceus with loss of teeth
Figure 5: A case of  Pemphigus vulgaris with pigmented palms after 
DCP
Figure 6: A case of  Pemphigus vulgaris with diffuse pigmentation of 
nails after DCP
PROFORMA
Name :
Age / Sex :
Occupation :
Income :
S/E status :
Address :
General history
• HT / DM       :
• PT / Heart disease       :
• Malignancy       :
• Smoking / Alcohol       :
• Precipitating factor       :
o Drugs               :
o Infection          :
o Diet                 :
o Trauma :
o Sweating :
o Sun exposure :
• Oral / Genital herpes     :
•
Family History
• Marital status       :
• Children       :
• Obstetric history       :
• P / S done or not       :
• Menstrual history       :
• H/O other auto immune
disease in the patient     :
• H/O auto immune 
diseases in relatives      :
H/O Vesiculobullous disease
• Date of onset       :
• Site of first lesion       :
(mucosal / skin)
• Morphology of first 
skin lesion and its 
evolution        :
• Treatment received        :
• Date of registration at 
GRH        :
• Number of exacerbations :
Onset Duration PPt. factors Treatment
                                         
                                         
                                        Conditions on first visit
 General condition
• Wt :
• CVS :
• RS :
• Abd :
• Others :
 Oral lesion
 Active skin lesions
• Number of bullae :
• Distribution – groups / discrete/
Along lines of trauma :
• Tense / flaccid :
• Contents – clear / pustular /
Hemorrhagic :
• Nikolsky sign & 
Bulla spread sign :
• Are of erosions :
• Symptoms :
 Healing skin lesions
• Hyper / hypo pigmentation :
• Milia :
• Scarring :
• Peripheral extension :
                                                     
Investigations
LFT
RFT
Sr. Electrolytes
Hemogram
ECG
Tzanck smear
Biopsy and
DIF
Semen analysis
USG abdomen
Ophthal examn
Others Chest X-ray, Stool examination for occult blood, Baseline fitz 
Patrick skin typing.
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Remarks
Banu 30/f PV 14 P A A A A A A A A P A A A P A A A A A
Indu 35/F PV 26 A A A A A A A A A P A P A P A A P A A Ovarian atrophy
Valli 45/F PV 13 A A A A A A A P A A A P A A A A A A A Cataract
Baby 33/F PE 18 A A P A A A A A A P A A A P A A A A A
Andichi 50/F PV 16 A A A A A A A P A A A A A A A A A A P
Mumtaj 42/F PV 14 A A A A A A P A A A A A A A A A A A A DM
Ramu 57/F PF 18 A A A A A A A A A A A P A A A A A A A Skin pigmentation
Ramathilagam 40/F PV 30 A A A A A A A A A P A A A A A A A A A Ovarian atrophy
Pattanichi 42/F PV 17 A A A A A A A A A A A A P A A A A A A
Rakha 18/F PF 16 A P P P A A A A A A A A A A A A A A A Died-septicaemia
Latha 38/F PV 13 P A A A A A A A A P A A A P A A A P P
Vanaja 42/F PV 12 A P A P A A A A A A A A A A A A A A A Died-septicaemia
Muthulakshmi 42/F PV 16 A A A A A A A A A A A A A A A A A A A
Manohari 44/F PV 30 A P A P A A P A A A A A A A A A A A A Died-septicaemia
Muthu venkat 53/F PV 16 A A A A A A A A A A A P A A A P A A A
Suresh 30/M PV 24 A A A A A A A A A A P A A A A A A A A
Dekolin 28/M PV 28 A A A A A A A A A A P A P A A A A A A Pigmented nail
Vijay 25/M PF 16 A A A A P A A A A A P A A A A A A A A KVCE
Arumugan 48/M PV 13 A A A A A A A P A A P P A A A A A A A
Anbu 35/M PF 14 A A A A A A A A A A P A A A P A A A A Teeth loss
Karthik 23/M PV 26 A A A A A A A A A A P A A A A A A A A
Karupiah 50/M PF 12 A A A A A A P A A A A P A A A A A A A Left-long distance
Raja rathnam 58/F PF 5 A A A A A A A A A A A A A A A A A A A Left-long distance
Siva 55/M PF 3 A A A A A A A A P A A A A A AA A A A A Left-hemorrhagic 
cystitis
Selvaraj 38/M PV 14 A A A A A A A A A A P P A A A A A A A
indrani 28/F PV 29 A A A A A A A A A P A P A P A A A A A
KEY TO MASTER CHART
PV= pemphigus vulgaris
PF= pemphigus foliaceus
PE= pemphigus erythematosus
P=  present
A= absent
HTN= hypertension
DM= diabetes mellitus
KVCE= Kaposi’s varicelliform eruption.
